Table 1.
CBCs in metformin-treated Fancd2−/− and Fancd2+/+ mice
| Blood counts | Fancd2−/− placebo | Fancd2−/− MET | P | Fancd2+/+ placebo | Fancd2+/+ MET | P | P (mutant placebo vs wild-type placebo) |
|---|---|---|---|---|---|---|---|
| WBCs, ×103/µL | 4.1 ± 0.2 | 5.1 ± 0.4 | <.05 | 5.5 ± 0.4 | 6.8 ± 0.5 | <.05 | <.003 |
| RBCs, ×106/µL | 8.9 ± 0.1 | 9.3 ± 0.2 | .08 | 9.5 ± 0.1 | 9.7 ± 0.2 | .24 | <.01 |
| Hb, g/dL | 12.8 ± 0.1 | 13.5 ± 0.2 | <.005 | 13.5 ± 0.2 | 13.6 ± 0.2 | .80 | <.003 |
| HCT, % | 49.5 ± 0.5 | 51.2 ± 0.8 | .07 | 51.3 ± 0.8 | 51.6 ± 0.8 | .76 | .08 |
| MCV, fL | 55.6 ± 0.5 | 55.3 ± 0.3 | .59 | 53.0 ± 0.3 | 53.4 ± 0.8 | .49 | <.0001 |
| MCH, pg | 14.4 ± 0.2 | 14.6 ± 0.1 | .40 | 14.1 ± 0.2 | 14.0 ± 0.1 | .52 | .24 |
| MCHC, g/dL | 25.9 ± 0.2 | 26.3 ± 0.2 | .16 | 26.6 ± 0.2 | 26.2 ± 0.1 | .11 | <.05 |
| PLT, ×103/µL | 404 ± 17 | 465 ± 20 | <.05 | 530 ± 19 | 562 ± 28 | .37 | <.0001 |
Data were pooled results from multiple mice (17-19 mice each group) and presented as mean value ± standard error of the mean.
Hb, hemoglobin; HCT, hematocrit; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MET, metformin; PLT, platelet; RBC, red blood cell; WBC, white blood cell.